Blood Collection From Individuals With Lung Disease for Genetic Studies (Qatar) - Full Text View

Purpose

This is a research study where researchers are collecting blood to evaluate the genetic characteristics of individuals with chronic lung diseases, including asthma, COPD (chronic obstructive pulmonary disease), interstitial lung disease, cystic fibrosis, and lung cancer. The investigators hope to be able to identify an association between a genetic make-up in the blood samples and the risks of developing a particular lung disease, or severity of a lung disease. The findings of this study might be important to develop future preventative methods and potential treatments for the management of lung disease.

Condition
Asthma COPD Interstitial Lung Disease Cystic Fibrosis Lung Cancer


Study Type:	Observational
Study Design:	Observational Model: Case Control Time Perspective: Prospective
Official Title:	Collection of Blood for Gene Expression Study in Individuals With Chronic Lung Diseases (Qatar)

Resource links provided by NLM:

Genetics Home Reference related topics: cystic fibrosis pulmonary alveolar microlithiasis

MedlinePlus related topics: Asthma Cystic Fibrosis Interstitial Lung Diseases Lung Diseases

Genetic and Rare Diseases Information Center resources: Cystic Fibrosis

U.S. FDA Resources

Further study details as provided by Weill Medical College of Cornell University:

Biospecimen Retention: Samples With DNA

This protocol is designed to collect a small amount of blood for extraction of DNA (genetic material) for the study of the genetic basis of lung disease. Genomic DNA will be extracted, and genome wide SNP analysis and promoter sequences for genes will be obtained. The goal is to find single nucleotide polymorphims (SNP), small changes in single genes that affect disease risk, to see if they correlate with lung disease.


Estimated Enrollment:	600
Study Start Date:	May 2006
Study Completion Date:	May 2012

Groups/Cohorts
1: Lung Disease Individuals with at least one of the following: (1) symptoms consistent with pulmonary disease; (2) chest X-ray consistent with lung disease; (3) pulmonary function tests consistent with lung disease; (4) lung biopsy consistent with lung disease; (5) family history of lung disease; (6) patients with diseases of organs with known association with lung disease; and (7) individuals suspected of history of lung diseased based on history and/or physical examination
2: Normal Control Individuals without a history of lung disease.

Groups/Cohorts

1: Lung Disease

Individuals with at least one of the following: (1) symptoms consistent with pulmonary disease; (2) chest X-ray consistent with lung disease; (3) pulmonary function tests consistent with lung disease; (4) lung biopsy consistent with lung disease; (5) family history of lung disease; (6) patients with diseases of organs with known association with lung disease; and (7) individuals suspected of history of lung diseased based on history and/or physical examination

2: Normal Control

Individuals without a history of lung disease.

Detailed Description:

This protocol is designed to collect a small amount of blood for extraction of DNA (genetic material) for the study of the genetic basis of lung disease. The study population will include individuals with known lung diseases and controls without lung disease. Individuals in the study population will be individuals at the Hamad Medical Corporation, Qatar (HMC), as well as other individuals recruited for this study. In this protocol, researchers will survey medical records of patients with chronic lung disease, in order to study the clinical characteristics of these individuals, and the researchers will collect blood to evaluate the genetic characteristics of individuals with chronic lung diseases including asthma, and COPD (chronic obstructive pulmonary disease), pulmonary fibrosis, and lung cancer. The researchers will also collect blood samples of individuals without lung disease to serve as control.

This protocol, to be carried out at Weill Cornell Medical College - Qatar and Hamad Medical Corporation, Qatar, parallels a similar approved protocol IRB #0508008095, entitled, "Collection of Blood for Gene Expression/Genomic Studies in Individuals with Chronic Lung Diseases", ongoing at Weill Cornell Medical College - New York.

Eligibility


Ages Eligible for Study:	18 Years to 90 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes
Sampling Method:	Non-Probability Sample

Study Population

Individuals visiting the Medicine Department at the Hamad Medical Corporation, Qatar for standard clinical care will be recruited.

Controls will be obtained from volunteers without a history of lung disease. Family members of patients may be asked to participate in the study.

Criteria

Lung Disease group. Individuals with lung disease who fit the following criteria will be enrolled.

Inclusion criteria

Must provide informed consent
Males and females, age 18 years and older
Evidence of lung disease proven by at least one of the following: (1) symptoms consistent with pulmonary disease; (2) chest X-rays and/or chest CT consistent with lung disease; (3) pulmonary function tests consistent with lung disease; (4) lung biopsy consistent with lung disease; (5) family history of lung disease; and (6) diseases of organs with known association with lung disease; and (7) individuals suspected of history of lung diseased based on history and/or physical examination

Exclusion criteria

Individual refuses consent.

Normal control group. For the purpose of this protocol, "normal" will include individuals without history of chronic lung disease, including asthma, and without recurrent or recent (within 3 months) acute pulmonary disease, and will be determined by the following criteria:

Inclusion Criteria:

Must provide informed consent.
Males or females ages 18 years and older.
Non-smokers, ex-smokers and smokers.

Exclusion Criteria:

Individual refuses consent.
Individuals with history of chronic lung disease, including asthma or with recurrent or recent (within three months) acute pulmonary disease will not be accepted into the study.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00504361

Locations


Qatar
Hamad Medical Corporation
Doha, Qatar

Sponsors and Collaborators

Weill Medical College of Cornell University

Weill Cornell Medical College in Qatar

Hamad Medical Corporation

Investigators


Principal Investigator:	Ronald G Crystal, MD	Weill Cornell Medical College, NY and Qatar

More Information

No publications provided


Responsible Party:	Weill Medical College of Cornell University
ClinicalTrials.gov Identifier:	NCT00504361 History of Changes
Other Study ID Numbers:	0605008516, HMC RC#373/2006
Study First Received:	July 19, 2007
Last Updated:	December 19, 2013
Health Authority:	United States: Institutional Review Board Qatar: Hamad Medical Corporation

Keywords provided by Weill Medical College of Cornell University:


Asthma COPD Interstitial Lung Disease Cystic Fibrosis	Lung Cancer smokers non-smokers

Additional relevant MeSH terms:


Cystic Fibrosis Lung Diseases Lung Diseases, Interstitial Digestive System Diseases	Genetic Diseases, Inborn Infant, Newborn, Diseases Pancreatic Diseases Respiratory Tract Diseases

ClinicalTrials.gov processed this record on March 03, 2015

Blood Collection From Individuals With Lung Disease for Genetic Studies (Qatar) (Q-BC)